Innate Pharma Announces That It Will Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data At AACR 2024
Portfolio Pulse from Benzinga Newsdesk
Innate Pharma announced its plans to present preclinical data for its Nectin-4 antibody drug conjugate, IPH45, at the AACR Annual Meeting 2024. The data supports further development of IPH45, a topoisomerase I inhibitor ADC targeting Nectin-4, as it progresses towards clinical trials.
March 06, 2024 | 8:01 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Innate Pharma's announcement about presenting IPH45 preclinical data at AACR 2024 highlights the progress of its Nectin-4 targeting ADC towards clinical trials.
The announcement of presenting IPH45 preclinical data at a prestigious conference like AACR 2024 is a positive development for Innate Pharma. It indicates progress in their pipeline and potential for future growth as IPH45 moves closer to clinical trials. This news is likely to be viewed positively by investors, potentially leading to an increase in stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90